Traws Pharma is a clinical-stage biopharmaceutical company developing oral small molecule therapies for respiratory viral diseases and cancer, utilizing small molecule chemistry and artificial intelligence for rational drug design. The company targets the issue of acquired resistance to existing medications, focusing on delivering effective treatments for vulnerable populations.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Respiratory viral diseases and cancer often develop resistance to existing medications, leading to ineffective treatments, especially for vulnerable populations. Current therapies may not adequately address the evolving nature of these diseases, creating a need for new treatment options.
Solution
Traws Pharma is developing oral small molecule therapies for respiratory viral diseases and cancer, designed to overcome acquired resistance. The company utilizes small molecule chemistry and artificial intelligence for rational drug design, aiming to deliver effective treatments. Their approach focuses on identifying and developing novel product candidates that address unmet medical needs in these therapeutic areas. By leveraging expertise in drug design and streamlined development, Traws Pharma seeks to provide innovative medicines that target critical threats to human health.
Target Audience
The primary target audience includes patients with respiratory viral diseases and cancer, particularly those who have developed resistance to existing treatments, as well as healthcare providers seeking new therapeutic options.
Features
- Oral small molecule therapies for respiratory viral diseases and cancer
- Focus on overcoming acquired resistance to existing medications
- Utilizes small molecule chemistry and artificial intelligence for rational drug design
- Clinical-stage development programs
- Investigational one-dose influenza therapy, tivoxavir marboxil